Immunocore Holdings plc (NASDAQ:IMCR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Immunocore Holdings plc (NASDAQ:IMCR) has been given an average recommendation of “Moderate Buy” by the thirteen research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $65.64.

IMCR has been the subject of a number of research reports. Guggenheim downgraded Immunocore from a “buy” rating to a “neutral” rating in a report on Monday, October 7th. HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research note on Thursday, October 24th. Needham & Company LLC reiterated a “buy” rating and issued a $71.00 price objective on shares of Immunocore in a research note on Friday. Mizuho downgraded shares of Immunocore from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $72.00 to $38.00 in a research report on Monday, November 11th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $35.00 price target (down from $74.00) on shares of Immunocore in a research report on Friday, December 13th.

Hedge Funds Weigh In On Immunocore

A number of institutional investors and hedge funds have recently bought and sold shares of IMCR. Wellington Management Group LLP lifted its stake in Immunocore by 10.5% in the 3rd quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company’s stock worth $219,430,000 after purchasing an additional 668,382 shares in the last quarter. FMR LLC lifted its position in Immunocore by 0.5% during the third quarter. FMR LLC now owns 4,836,040 shares of the company’s stock worth $150,546,000 after buying an additional 23,436 shares in the last quarter. Primecap Management Co. CA boosted its stake in Immunocore by 26.7% during the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock worth $76,954,000 after buying an additional 520,950 shares during the last quarter. Bellevue Group AG grew its holdings in Immunocore by 4.4% in the 3rd quarter. Bellevue Group AG now owns 1,205,464 shares of the company’s stock valued at $37,526,000 after buying an additional 50,810 shares in the last quarter. Finally, Armistice Capital LLC increased its stake in shares of Immunocore by 495.1% in the 2nd quarter. Armistice Capital LLC now owns 976,000 shares of the company’s stock worth $33,077,000 after acquiring an additional 812,000 shares during the last quarter. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Price Performance

Shares of IMCR stock opened at $30.40 on Friday. The firm has a market capitalization of $1.52 billion, a price-to-earnings ratio of -32.00 and a beta of 0.76. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. The stock’s 50-day simple moving average is $31.16 and its 200-day simple moving average is $33.75. Immunocore has a fifty-two week low of $27.69 and a fifty-two week high of $76.98.

Immunocore (NASDAQ:IMCR) last released its earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.50. The company had revenue of $80.25 million for the quarter, compared to the consensus estimate of $78.94 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. During the same quarter in the previous year, the firm earned ($0.59) EPS. Immunocore’s revenue was up 23.7% compared to the same quarter last year. As a group, equities analysts forecast that Immunocore will post -0.94 earnings per share for the current fiscal year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.